Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M95,038Revenue $M7,670Net Margin (%)26.1Z-Score7.1
Enterprise Value $M94,363EPS $2.4Operating Margin %32.8F-Score8
P/E(ttm))49.3Cash Flow Per Share $4.4Pre-tax Margin (%)30.3Higher ROA y-yY
Price/Book14.510-y EBITDA Growth Rate %0Quick Ratio4.4Cash flow > EarningsY
Price/Sales12.95-y EBITDA Growth Rate %23.1Current Ratio4.6Lower Leverage y-yN
Price/Cash Flow17.9y-y EBITDA Growth Rate %39.3ROA % (ttm)13.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)36.7Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M801ROI % (ttm)17.8Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGRonald Muhlenkamp 2014-12-31 Reduce-1.03%$86.38 - $118.68
($105.53)
$ 118.7111%Reduce -41.31%86,240
CELGJoel Greenblatt 2014-12-31 Buy 0.01%$86.38 - $118.68
($105.73)
$ 118.7111%New holding10,259
CELGGeorge Soros 2014-09-30 Sold Out -0.45%$83.13 - $96.21
($90.29)
$ 118.7124%Sold Out0
CELGJoel Greenblatt 2014-09-30 Sold Out -0.07%$83.13 - $96.21
($90.29)
$ 118.7124%Sold Out0
CELGKen Fisher 2014-09-30 Add0.02%$83.13 - $96.21
($90.29)
$ 118.7124%Add 77.12%232,137
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 118.7136%Reduce -51.74%144,140
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 118.7136%New holding688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 118.7136%New holding63,980
CELGKen Fisher 2014-06-30 Add0.01%$68.45 - $86.8
($75.89)
$ 118.7136%Add 75.59%131,064
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.51)
$ 118.7133%Sold Out0
CELGKen Heebner 2013-06-30 Sold Out -0.79%$56.1 - $65.09
($60.18)
$ 118.7149%Sold Out0
CELGJoel Greenblatt 2013-06-30 Sold Out -0.01%$56.1 - $65.09
($60.18)
$ 118.7149%Sold Out0
CELGGeorge Soros 2011-03-31 Sold Out $24.75 - $30.01
($27.24)
$ 118.7177%Sold Out0
CELGGeorge Soros 2010-03-31 Sold Out -0.01%$27.39 - $32.51
($29.65)
$ 118.7175%Sold Out0
CELGDavid Swensen 2009-12-31 Sold Out $25.11 - $28.66
($27.12)
$ 118.7177%Sold Out0
CELGKen Heebner 2009-09-30 Sold Out -0.28%$23.01 - $28.9
($26.08)
$ 118.7178%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KAPLAN GILLADirector 2015-02-26Sell15,000$122.89-3.42view
CASEY MICHAEL DDirector 2015-02-25Sell15,000$123.19-3.65view
KARSEN PERRY Asee remarks 2015-02-11Sell27,896$120.12-1.19view
Alles Mark JSee Remarks 2015-02-06Sell117,099$120.68-1.65view
STEIN LAWRENCE VSee Remarks 2015-01-15Sell26,666$120.01-1.1view
KAPLAN GILLADirector 2015-01-02Sell45,536$113.474.6view
Daniel Thomas Osee remarks 2014-12-15Sell30,000$115.063.15view
KAPLAN GILLADirector 2014-12-08Sell15,000$118.20.41view
Daniel Thomas Osee remarks 2014-11-24Sell33,818$110.277.64view
KARSEN PERRY Asee remarks 2014-11-12Sell39,420$107.2310.69view

Press Releases about CELG :

Quarterly/Annual Reports about CELG:

News about CELG:

Articles On GuruFocus.com
February Pick Of Biotech Stocks Feb 17 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
You Can No Longer Ignore Biotech Feb 07 2014 

More From Our Partners
Why Goldman Sachs Is Wrong About These 3 Stocks - Analyst Blog Apr 15 2015 - ZACKS

More From Other Websites
Celgene Earnings Preview: What You Need to Know Apr 24 2015
Investors seek protection against healthcare stock decline Apr 24 2015
Investors seek protection against healthcare stock decline Apr 24 2015
Midday Glance: Biotechnology companies Apr 24 2015
Midday Glance: Biotechnology companies Apr 24 2015
AstraZeneca's Deals Prompt Doubts About Quality Apr 24 2015
Early Glance: Biotechnology companies Apr 24 2015
Early Glance: Biotechnology companies Apr 24 2015
AstraZeneca forced to defend cancer drug deal with Celgene Apr 24 2015
AstraZeneca insists Celgene deal about strategy, not cash Apr 24 2015
AstraZeneca insists Celgene deal about strategy, not cash Apr 24 2015
AstraZeneca insists Celgene deal about strategy, not cash Apr 24 2015
Cramer's Stop Trading: Regeneron gets to $500 Apr 24 2015
AstraZeneca Reports Fall in First-Quarter Profit Apr 24 2015
AstraZeneca looks beyond Nexium hit with new cancer deals Apr 24 2015
AstraZeneca looks beyond Nexium hit with new cancer deals Apr 24 2015
AstraZeneca looks beyond Nexium hit with new cancer deals Apr 24 2015
Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop... Apr 24 2015
Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop... Apr 24 2015
AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1... Apr 24 2015
Biogen Earnings Preview: What To Look For Apr 23 2015
5:44 pm Celgene announces POMALYST (pomalidomide) label update including progression-free and... Apr 23 2015
POMALYST® (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits... Apr 23 2015
Should Biogen and Shire investors be wary of the latest patent challenges? Apr 23 2015
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Meetings in May Apr 23 2015
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Meetings in May Apr 23 2015
CELGENE CORP /DE/ Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation... Apr 20 2015
How To Invest In ETFs: Tips To Trade Top Market Trends Apr 17 2015
Biotech giants present new data Apr 16 2015
Phase II Data for Apremilast in Behçet’s Disease Published in The New England Journal of Medicine Apr 15 2015
CELGENE CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Apr 15 2015
Celgene Corporation Elects Mr. Michael W. Bonney to Its Board of Directors Apr 15 2015
Celgene Corporation Elects Mr. Michael W. Bonney to Its Board of Directors Apr 15 2015
Celgene And Mesoblast Enter Into Agreement Apr 12 2015
Celgene Corporation to Announce First Quarter 2015 Results on April 30, 2015 Apr 01 2015
Celgene Corporation Announces the Appointment of Gerald F. Masoudi as Executive Vice President,... Apr 01 2015
Celgene Corporation (Nasdaq: CELG) to Ring The Nasdaq Stock Market Closing Bell Mar 31 2015
MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration Mar 26 2015
Ad hoc: MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration and MorphoSys Updates its... Mar 26 2015
MorphoSys AG : MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration Mar 26 2015
Phase II Data for Celgene's Investigational Oral GED-0301 for Patients with Active Crohn's Disease... Mar 18 2015
Open Monoclonal Technology Announces OmniAb™ Alliance with Celgene Mar 10 2015
Celgene Encourages Psoriatic Arthritis Patients to “pSAY YES!” a Different Approach to Disease... Feb 25 2015
ABRAXANE® Now Reimbursed in Italy as a First-Line Treatment of Adult Patients with Metastatic... Feb 24 2015
Celgene Corporation to Webcast at Upcoming Investor Conferences Feb 19 2015
Celgene Reports Fourth Quarter and Full Year 2014 Operating and Financial Results Feb 11 2015
Celgene tops 4Q profit forecasts Jan 29 2015
EU Oks new Celgene pill for psoriasis, psoriatic arthritis Jan 16 2015
Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global... Jan 12 2015
Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results Jan 12 2015
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators' Choice in... Dec 16 2014
Results from Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plus Low-Dose dexamethasone in... Dec 16 2014
Europe gives green light to AbbVie hepatitis C medicine, others Nov 21 2014
Celgene beats Street 3Q forecasts Oct 23 2014
Drug firm exec gets 16 months in inside-trade case Apr 22 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK